Form 8-K - Current report:
SEC Accession No. 0000950170-24-122824
Filing Date
2024-11-07
Accepted
2024-11-07 08:08:15
Documents
13
Period of Report
2024-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mbx-20241107.htm   iXBRL 8-K 40088
2 EX-99.1 mbx-ex99_1.htm EX-99.1 113744
3 GRAPHIC img258572290_0.jpg GRAPHIC 10199
  Complete submission text file 0000950170-24-122824.txt   299408

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mbx-20241107.xsd EX-101.SCH 26956
15 EXTRACTED XBRL INSTANCE DOCUMENT mbx-20241107_htm.xml XML 5116
Mailing Address 12406 HORESHAM STREET CARMEL IN 46032
Business Address 12406 HORESHAM STREET CARMEL IN 46032 3179893100
MBX Biosciences, Inc. (Filer) CIK: 0001776111 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42272 | Film No.: 241433300
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)